Immunotherapy advances for mesothelioma treatment

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2017-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14737140.2017.1358091PMID 28724330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T cell exhaustion: from pathophysiological basics to tumor immunotherapy

  2017cited by this paper
• ED05.02 Update on the Mesothelioma Staging System

  2017influential reference
• Anti-CTLA-4 therapy for malignant mesothelioma.

  2017influential reference
• Radiation therapy for malignant pleural mesothelioma.

  2017cited by this paper
• Immune microenvironment in mesothelioma: Looking beyond PD-L1.

  2017cited by this paper
• Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.

  2017cited by this paper
• Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

  2017cited by this paper
• Current and prospective pharmacotherapies for the treatment of pleural mesothelioma

  2017influential reference
• FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

  2017cited by this paper
• Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.

  2016cited by this paper
• Cancer immunotherapy: the beginning of the end of cancer?

  2016cited by this paper
• Persistence of androgen receptor (AR) expression in patients (pts) with small cell prostate cancer (SCPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

  2016cited by this paper
• Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.

  2016cited by this paper
• Harnessing the immune system to improve cancer therapy.

  2016influential reference
• Switching off malignant mesothelioma: exploiting the hypoxic microenvironment

  2016cited by this paper
• Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.

  2016cited by this paper
• Immunotherapy for malignant mesothelioma: reality check

  2016cited by this paper
• Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).

  2016cited by this paper
• Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).

  2016cited by this paper
• Malignant pleural mesothelioma: new ideas needed

  2015influential reference
• Tremelimumab for the treatment of malignant mesothelioma

  2015cited by this paper
• Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

  2015cited by this paper
• Human natural killer cells promote cross‐presentation of tumor cell‐derived antigens by dendritic cells

  2015cited by this paper
• Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

  2015cited by this paper
• Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.

  2015cited by this paper
• Oncolytic virotherapy for human malignant mesothelioma: recent advances

  2015influential reference
• Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028

  2015cited by this paper
• Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.

  2014cited by this paper
• Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

  2014cited by this paper
• Therapies currently in Phase II trials for malignant pleural mesothelioma

  2013cited by this paper
• Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

  2013cited by this paper
• Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

  2013cited by this paper
• Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

  2013cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013cited by this paper
• Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Cancer and Radiation Therapy: Current Advances and Future Directions

  2012cited by this paper
• Inflammation in malignant mesothelioma - friend or foe?

  2012cited by this paper
• Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

  2012cited by this paper
• Malignant mesothelioma: Facts, Myths, and Hypotheses

  2012cited by this paper
• Mesothelioma: a review.

  2012influential reference
• A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

  2011cited by this paper
• Germline BAP1 mutations predispose to malignant mesothelioma

  2011cited by this paper
• Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

  2011cited by this paper
• Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.

  2011cited by this paper
• Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181))

  2011cited by this paper
• What's the place of immunotherapy in malignant mesothelioma treatments?

  2010cited by this paper
• Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

  2010cited by this paper
• Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

  2010cited by this paper
• Adaptive immunity.

  2010cited by this paper
• WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer

  2010cited by this paper
• Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.

  2010cited by this paper
• Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation

  2010cited by this paper
• Adaptive Immunity

  2009influential reference
• Malignant pleural mesothelioma: current treatments and emerging drugs

  2009cited by this paper
• Ionizing radiation: a risk factor for mesothelioma

  2009cited by this paper
• Pathology of mesothelioma

  2008cited by this paper
• Malignant mesothelioma

  2008cited by this paper
• Linking innate to adaptive immunity through dendritic cells.

  2008cited by this paper
• The relationship between simian virus 40 and mesothelioma

  2008cited by this paper
• Advances in the systemic therapy of malignant pleural mesothelioma

  2008cited by this paper
• Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center

  2007cited by this paper
• Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

  2007cited by this paper
• Malignant pleural mesothelioma: a comprehensive review.

  2006influential reference
• TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis

  2006cited by this paper
• Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.

  2005cited by this paper
• Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.

  2004cited by this paper
• Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

  1998cited by this paper
• Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

  1998cited by this paper
• Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice

  1991cited by this paper
• Lymphocytic infiltration of pleural mesothelioma and its significance for survival.

  1982cited by this paper
• Extended Tumor Control after Dendritic Cell Vaccination with Low Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma at a Glance Commentary

  year unknowncited by this paper

• Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis

  2025cites this paper
• Intratumor microbiota as a novel potential prognostic indicator in mesothelioma

  2023cites this paper
• The Association between the Histological Subtypes of Mesothelioma and Asbestos Exposure Characteristics

  2022cites this paper
• Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma

  2022cites this paper
• Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives

  2020cites this paper
• The role and therapeutic implications of T cells in cancer of the lung

  2019cites this paper
• The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies

  2019cites this paper
• The Future of Mesothelioma Research: Basic Science Research

  2019cites this paper
• What can independent research for mesothelioma achieve to treat this orphan disease?

  2019cites this paper
• Caring for Patients with Mesothelioma: Principles and Guidelines

  2019cites this paper
• Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994‐2013)

  2018cites this paper
• p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification

  2018cites this paper
• New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma

  2018cites this paper